Summary Cisplatin (CDDP) was microcapsulated with ethylcellulose. Sustained release of CDDP from the microcapsule, particularly non-protein-bound CDDP, which should have antitumour activity, was demonstrated by an in vitro test. Using a bioassay, it was proven that the biological activity of CDDP was not affected by the microencapsulation process.
Cisplatin (CDDP) is one of the most powerful antineoplastic agents and response rates up to 40% in patients with tumours of the testis or ovary, have been demonstrated (Merrin, 1976) . CDDP has also been reported to be effective against carcinoma of the head and neck (Wittes, 1977; Muggia, 1980) . However, it produces many side effects, such as renal disturbance, vomiting, nausea and auditory disturbance. Among these, renal disturbance is the major problem.
Since antineoplastic agents have no selective toxicity for cancer cells, effort should be concentrated upon improving therapeutic efficacy at the same time as minimizing side effects.
Using the conventional method of injecting drugs into the artery serving the tumour, the agents flow into the general circulation rapidly, and it is difficult to keep in situ drug concentrations high.
Mitomycin-C microcapsule (Mitomycin-C, encapsulated with ethylcellulose) chemoembolization was developed by colleagues (1979, 1981) who showed a significant effect on tumours of the urinary tract and liver.
In our study CDDP was encapsulated with ethylcellulose and basic and clinical observations recorded.
Materials and methods
Effect of CDDP on L-cell proliferation L-cells derived from mouse fibroblasts were cultivated in MEM (Nishui Co., Ltd.) containing 10% foetal calf serum at 37°C.
After treatment with EDTA-trypsin, the cell suspension was adjusted to 5 x 104/tube and cultivated for 24 h at 37°C. The culture media were then exchanged with media containing CDDP (Bristol Co., Ltd.) Encapsulation of CDDP CDDP was encapsulated with ethylcellulose by using the method of coacervation with certain modifications described for mitomycin-C microcapsules (Kato et al., 1978) , and sterlilized at 1350C for 2h. CDDP-microcupsules (CDDP-mc) consist of 60% (w/w) CDDP (Bristol Co., Ltd.) (Figure 1 ). The estimation of CDDP from the microcapsule was examined as follows.
Human serum was drawn (2.5ml/lOmin) into a Swinnex-13 with HA filter (Millipore Corporation) containing lmg of CDDP-mc. The outflow was collected by a fraction collector and the CDDP concentration determined. During the experiment, filter units were kept at 37°C in a water bath. Possible alteration of the biological activity of CDDP follow the encapsulation process was examined by the following two methods. Here, the elution from CDDP-mc in saline was used to evaluate the bioactivity of CDDP-mc.
In the first method (Rec assay) using Bacillus subtilis inhibition of the H-17 (Rec+) strain was compared with the M-45 (Rec-) strain (Sadaie et al., 1976) . Briefly, bacterial suspensions were streaked, in the shape of the letter 'V' on nutrient agar plates (see Figure 5) . A paper disc (8mm in diameter) dipped with CDDP or CDDP-mc (each concentration, 0.5mg) was placed on the apex of the 'V'. The plates were incubated overnight at 37°C and bacterial growth was determined.
In CDDP-mc suspended in saline (-60mg per 60ml) was infused into the maxillary artery or the lingual artery.
During infusion, the superficial temporalis artery was pressed at the preauricular region to prevent inflow of CDDP-mc.
After administration of the drug, blood samples were collected at various time intervals and total urine collections were made for 7 days in order to determine the CDDP concentration.
Biopsies were performed on 5 patients with maxillary cancer at 1 h, 3 days and 7 days after administration. The biopsied specimen was homogenized in saline containing 1:1000 of Triton X-100 and the final concentration of homogenate was adjusted to 1:2 (w/v). The total platinum level was then determined.
As controls, patients with maxillary cancers were given non-encapsulated CDDP. CDDP 60mg was administered to 3 patients by continuous peripheral i.v. infusion over 24 h, and 20 mg CDDP was administered into the maxillary artery of 3 patients in 5 mmn.
The patients, given unencapsulated CDDP or CDDP-mc were hydrated with 2000 ml saline prior to the drug administration and hydration was maintained for 7 days after the administration in order to increase urine output.
The quantity of CDDP in the clinical specimen was determined by a Perkin-Elmer model 403 atomic absorption spectrophotometer with heated graphite atomizer (HGA 2100). The sample 20 Ml was applied to the atomizer and dried for 60 sec at 1 50°C, charred for 60 sec at 1 500°C (1900°C for biopsy specimen), and atomized at 2700°C for 15 sec. CDDP concentration was calculated from the platinum concentration.
Non protein-bound-CDDP concentration in the serum was determined after ultrafiltration by Centriflo CF-50A (Amicon Co., Ltd.). (Figure 4) . The results of the Rec assay are shown in Figure  5 . CDDP inhibited growth of the Rec-strain but not the Rec+ strain, and no difference was found in the activities of CDDP and CDDP-mc.
Growth of Pseud. aeruginosa was partially inhibited by 1.0 pg ml-of CDDP, but no difference was found between CDDP and CDDPmc.
Clinical study
The CDDP blood concentrations of patients who had received 60mg of CDDP-mc are shown in Figure 6 . Highest levels were detected 1-2 days after administration, then gradually decreased. All CDDP found in the blood was protein-bound.
CDDP concentrations in the biopsied cancer tissue taken from patients with maxillary tumours, who had been given 60mg of CDDP-mc, are shown in Figure 7 . The peak concentration in the tissues was found 3 days after drug administration, and the maximum level in each patient was 30-150 Mgg 1 wet tissue.
CDDP levels in the blood of patients who had been administered with 60mg of non-encapsulated CDDP by continuous infusion over 24h reached the maximum (2800ugml-1) just after completion of the infusion, and then decreased gradually (Figure 8) Cisplatin (cis-dichlorodiamine platinum (II), CDDP) is a water-soluble compound which has a platinum atom in the centre with 2 chlorine and 2 ammonia atoms located at the cis position. Rosenberg (1965) found that coli bacilli lost their splitting ability and formed a long filament in a solution using a platinum electrode. This observation led to the disclosure of the antibacterial effect, and subsequently the anti-tumour effect of platinum.
The anti-tumour effect of various platinum compounds has since been studied, with the eventual discovery of CDDP.
Since then clinical applications of CDDP were commenced and with the recognized effectiveness of (mean, 6.8%) of the total was dete 24h, and 22-25.5% (mean, 23.5%) in After administration of 60mg CI 23% (mean, 19%) was detected with 26-48% was found in 7 days. t'AjL'r on Lumours oI tne testLs ana ovary it nas )P-mc. CDDP become a popular anti-tumour drug (Merrin, 1976; t Rec+ strain, Wittes, 1977; Muggia, 1980 Figure 3 , protein- Microcapsules introduced into an artery serving the tumour region, easily cause embolism in the region because of their size. Hopefully, embolism would suppress the growth of the tumour.
The time-releasing property of the microcapsule is realised by the fact that a drug coated with ethylcellulose dissolves in the blood stream over a period of hours.
Combining these two principles, anti-cancer drugs can theoretically be administered to a tumour with greater specificity and efficacy. Moreover, if it is possible to maintain a high drug concentration in tumour only, their systemic side effects can be greatly reduced.
However, microcapsules containing mitomycin-C have been reported to cause occasionally incurable skin ulcers as a side effect (Kato et al., 1981) . The use of this drug, therefore was contraindicated for tumours of the head and neck.
In the present report, the efficacy of CDDP-mc was studied in the following areas: biological activity of CDDP eluted from CDDP-mc, CDDP 20 mg, blood concentrations were very high. To increase the dose is dangerous because the blood CDDP concentrations are reportedly correlated with renal disturbance (Campbell et al., 1981) . Accordingly we have evaluated microcapsule embolization containing CDDP. Microcapsule containing mitomycin-C developed by Kato et al. (1979; , have been recognized as a unique form of chemotherapy of tumours of the urinary tract and liver. The microcapsule acts on two basic principles: tumour vessel embolism, and timereleasing properties. concentration in cancer tissue, and responses and side effects after the administration of CDDP-mc.
CDDP is a fairly stable compound when exposed to heat, light, and pH variations (Galabres et al., 1975) . The biological activity of eluted CDDP from sterilized CDDP-mc was determined by the Rec assay and cell growth inhibition test.
As seen in Figure 5 , CDDP eluted from microcapsules showed similar activity to the starting CDDP and it is clear that the biological activity of CDDP can be preserved completely, even after the microcapsulization process. CISPLATIN MICROCAPSULE CHEMOEMBOLIZATION 375 The elution speed of CDDP from the microcapsule, determined by an in vitro system, showed a biphasic profile. In the first phase, the CDDP concentration in the eluate decreased quickly, from 4,900ngml-1 to 1,800ngml-1 in 6h. In the second phase, CDDP concentration decreased gradually, from 1,800 ng ml1 to 460ngml-1 in 32h.
When the blood CDDP concentration after administration of CDDP-mc was examined, it reached a peak 1-2 days later and its value was 600-1,400ngml-1. These cases account for I of the cases where an equivalent dose of CDDP was administered by drip infusion.
Using 60mg of CDDP-mc, the Pt concentration in biopsied cancer tissue reached its peak, which was 30-150igg-1 (wet weight). This was arrived at 3 days after administration, and gradually decreased.
With arterial infusion of 20mg non-encapsulized CDDP, the CDDP concentration in blood was very high (2,700-3,200ngml-1) but not in cancer tissue (3,000-7,000 ng g -1).
Using 100mg of ordinary CDDP i.v. Mattox et al. (1983) reported that the CDDP concentration in the cancer tissue was 1.5 gg-1, 2h, and 9.9pgg-6 h after injection.
The above results can not be compared. However, drug concentrations in target tissue can be kept at a higher level by the microcapsule technique than by the conventional administration technique. Especially, with the usual method of injection into the artery serving the neoplastic region, CDDP flows rapidly into the general circulation, making it difficult to keep the concentration high in the tumour.
Next, cases were presented in which only CDDPmc (40-60mg) was injected intra-arterially as an initial treatment (Table I) .
Of 14 patients, 9 subsequently had a marked tumour reduction of over 50% in measurable diameter (e.g. Figure 9 ). In addition to these cases, 7 cases who had received or were receiving radiation were treated with CDDP-mc.
Considering side effects, nausea and vomiting were observed in 12 out of the 21 cases. In none however, was renal hypofunction observed by either the PSP or the creatinine clearance tests. Buccal pain on the affected side was a common complaint in 14 cases. This, however, mostly controllable by the administration of an analgesic, and symptoms disappeared within 24 h. Auditory disturbance was not detected.
Thus, selective intra-arterial injection of CDDPmc could make it possible to treat cancers continuously and selectively, raising hopes that the therapeutic effect will be increased and the general side effects of CDDP reduced.
